Skip to main content

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock
WESTLAKE VILLAGE, Calif. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has commenced a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the
Toggle Summary Sienna Biopharmaceuticals Prices Public Offering of Common Stock
WESTLAKE VILLAGE, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $2.50 per share.
Toggle Summary Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations
-- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif. , March 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the promotion of Alexander Azoy to Chief Financial Officer (CFO). Mr.
Toggle Summary Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
WESTLAKE VILLAGE, Calif. , March 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results for the fourth quarter and full year of 2018. “We are pleased to report the results of our 2018
Toggle Summary Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
WESTLAKE VILLAGE, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the

SEC Filings

Filer Filing date Form Filing Group View
DEFA14A
Proxy Filings
View HTML
DEF 14A
Proxy Filings
View HTML
Azoy Alexander 4
Section 16 Filings (3,4,5)
View HTML
Azoy Alexander 3
Section 16 Filings (3,4,5)
View HTML

Events

Webcast events that have already occurred are presented for historical purposes only and speak only as of the date thereof.

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

Firm Analyst
J.P. Morgan
Chris Schott
Cowen
Ken Cacciatore
BMO Capital Markets
Gary Nachman

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Transfer Agent

EQ Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com